Shares of Q32 Bio (QTTB) lost nearly 77% yesterday after it reported mixed results from two separate phase IIa studies evaluating its investigational drug bempikibart  one in atopic dermatitis (AD or eczema) and the other in alopecia areata (AA).While data from the AA study showed promising clinical activity for the drug, the study did not meet its primary endpoint in part B of the eczema study.Based on the above results, management has decided to proceed with developing the drug for AA, but will no longer ...